All In Biotech

Drug Trial Radar · NCT05426733

An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia

An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia (BOLD-EXT)

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Jul 5, 2022

Primary completion

Oct 28, 2026

Study completion Oct 28, 2026

Sponsor

Lead sponsor
Albireo, an Ipsen CompanyIndustry
Sponsor type
Industry
First posted
Jun 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia

Conditions

  • Biliary Atresia

Interventions

  • OdevixibatDrug

    Odevixibat is a small molecule inhibitor of the ileal bile acid transporter (IBAT).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients who are alive and have not undergone liver transplantTime frame: From baseline to Week 104

Locations

30 sites in 14 countries. Site status is shown where the registry gives one.

  • Children's Hospital Colorado

    Aurora, Colorado

  • Children's Healhcare of Atlanta- Emory University school of medicine

    Atlanta, Georgia

  • Indiana University school of Medicine

    Indianapolis, Indiana

  • Boston Children's Hospital

    Boston, Massachusetts

  • Children's Mercy Hospital and Clinics

    Kansas City, Missouri

  • Hassenfeld Children's Hospital at NYU Langone

    New York, New York

  • Columbia University Medical Center New York Presbyterian Morgan Stanley-Komansky Childrens Hospital

    New York, New York

  • The Childrens Hospital at Montefiore Albert Einstein School of Medicine

    The Bronx, New York

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Seattle Children's Hospital

    Seattle, Washington

  • Royal Children's Hospital

    Parkville, Australia

  • CHU Sainte-Justine

    Montreal, Canada

  • The Hospital for Sick Children

    Toronto, Canada

  • Guangzhou Women And Childrens Medical Center

    Guangdong, China

  • Children's Hospital of Fudan University

    Shanghai, China

  • Bicêtre Hospital

    Le Kremlin-Bicêtre, France

  • Charité - Universitätsmedizin Berlin

    Berlin, Germany

  • University Children´s Hospital Tuebingen

    Tübingen, Germany

  • ASST Papa Giovanni XXIII

    Bergamo, Italy

  • Azienda Ospedaliera di Padova

    Padova, Italy

  • Hospital Raja Perempuan Zainab II

    Kota Bharu, Malaysia

  • University Malaya Medical Centre

    Kuala Lumpur, Malaysia

  • University Medical Center Groningen

    Groningen, Netherlands

  • Starship Child Health, Te Whatu Ora - Health New Zealand

    Auckland, New Zealand

  • Instytut Pomnik-Centrum Zdrowia Dziecka

    Warsaw, Poland

  • Seoul National University Childrens Hospital

    Seoul, South Korea

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hacettepe İhsan Doğramacı Children's Hospital

    Ankara, Turkey (Türkiye)

  • Akdeniz University Medical Faculty

    Antalya, Turkey (Türkiye)

  • Istanbul University Istanbul Medical Faculty Hospital

    Istanbul, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.